The targeted drug delivery devices market for biologics is projected to be worth around USD 5 billio
Driven by the urgent need to address off-target toxicity-related concerns and improve therapeutic outcomes of biologic drugs, several patient-centric medical devices that facilitate drug delivery to desired physiological regions, are being developed
Roots Analysis has announced the addition of “Organ–based / Targeted Drug Delivery Devices Market for Biologics (Intra-organ / Intra-tumoral), 2020 – 2030” report to its list of offerings.
Despite the many benefits offered by biologics, they are associated with a number of challenges, such as delivery-related complexities, immunogenicity concerns, compromised efficacy and need for periodic administration (cell therapies). To address some of these concerns, several innovator companies are actively engaged in identifying targeted and effective delivery strategies for biologics, including gene therapies, cell / stem cell therapies, immunotherapies and therapeutic proteins.